Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Farmers Insurance
Mallinckrodt
Chubb
Cantor Fitzgerald
Cipla
Moodys
Harvard Business School
UBS

Generated: December 10, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,737,112

« Back to Dashboard

Which drugs does patent 7,737,112 protect, and when does it expire?

Patent 7,737,112 protects KYPROLIS and is included in one NDA.

This patent has sixty-six patent family members in twenty countries.

Summary for Patent: 7,737,112
Title:Composition for enzyme inhibition
Abstract: Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.
Inventor(s): Lewis; Evan R. (Pacifica, CA), Ho; Mark Nguyen (San Jose, CA), Fonseca; Fabiana N. (New York, NY)
Assignee: Onyx Therapeutics, Inc. (South San Francisco, CA)
Application Number:11/299,265
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,737,112
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 7,737,112

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-003 Jun 7, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-002 Jun 3, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-001 Jul 20, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,737,112

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 499109 ➤ Sign Up
Australia 2005243140 ➤ Sign Up
Australia 2005243168 ➤ Sign Up
Australia 2005313975 ➤ Sign Up
Brazil PI0510802 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Boehringer Ingelheim
McKinsey
Fish and Richardson
AstraZeneca
UBS
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.